Global Chemotheraphy Induced Nausea and Vomitting CINV Drugs Market Research Report 2023(Status and Outlook)

Global Chemotheraphy Induced Nausea and Vomitting CINV Drugs Market Research Report 2023(Status and Outlook)

Report Overview

Chemotherapy-induced nausea and vomiting (CINV) is a common side-effect of many cancer treatments. Nausea and vomiting are two of the most feared cancer treatment-related side effects for cancer patients and their families. In 1983, Coates et al. found that patients receiving chemotherapy ranked nausea and vomiting as the first and second most severe side effects, respectively. Up to 20% of patients receiving highly emetogenic agents in this era postponed, or even refused, potentially curative treatments. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to better manage these symptoms in a large portion of patients. Efficient mediation of these unpleasant and sometimes crippling symptoms results in increased quality of life for the patient, and better overall health of the patient, and, due to better patient tolerance, more effective treatment cycles.

Affecting 70-80% of patients undergoing chemotherapy, chemotherapy-induced nausea and vomiting (CINV) is one of chemotherapy's most debilitating side effects, often attributed as a leading cause of premature discontinuation of cancer treatment.

Global Chemotheraphy Induced Nausea and Vomitting (CINV) Drugs key players include Haisco, Merck, Mundipharma, Qilu Pharma, Heron Therapeutics, Teva, etc. Global top six manufacturers hold a share about 30%.

North America is the largest market, with a share about 35%, followed by Europe and Asia-Pacific, both have a share about 60 percent.

In terms of product, 5-HT3 Inhibitors is the largest segment, with a share over 70%. And in terms of application, the largest application is Acute CINV, followed by Delayed CINV and Breakthrough CINV.

The Global Chemotheraphy Induced Nausea and Vomitting CINV Drugs Market Size was estimated at USD 2328.00 million in 2022 and is projected to reach USD 2079.45 million by 2029, exhibiting a CAGR of -1.60% during the forecast period.

Bosson Research’s latest report provides a deep insight into the global Chemotheraphy Induced Nausea and Vomitting CINV Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Chemotheraphy Induced Nausea and Vomitting CINV Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Chemotheraphy Induced Nausea and Vomitting CINV Drugs market in any manner.

Global Chemotheraphy Induced Nausea and Vomitting CINV Drugs Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Heron Therapeutics

Merck

Eisai

Mundipharma

Qilu Pharma

Teva

Novartis

Roche

Mylan

Baxter

GSK

Helsinn

Southwest Pharma

Haisco

Sun Pharma

Market Segmentation (by Type)

5-HT3 Inhibitors

NK1 Inhibitors

Others

Market Segmentation (by Application)

Communication

Consumer Electronics

Aerospace and Defense

Car

Others

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Chemotheraphy Induced Nausea and Vomitting CINV Drugs Market

Overview of the regional outlook of the Chemotheraphy Induced Nausea and Vomitting CINV Drugs Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors